Altimmune (ALT) Interest & Investment Income (2010 - 2026)
Altimmune (ALT) reported Interest & Investment Income of $2.9 million for Q1 2026, up 87.77% year-over-year from $1.5 million in Q1 2025, and up 18.99% on a QoQ basis from $2.4 million in Q4 2025.
Altimmune (ALT) has 15 years of Interest & Investment Income data on file, last reported at $2.9 million in Q1 2026.
- Quarterly Interest & Investment Income rose 87.77% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (up 23.47% YoY) and the FY2025 annual result came in at $7.5 million, down 6.6% from the prior year.
- Interest & Investment Income climbed to $2.9 million in Q1 2026 per ALT's latest filing, from $2.4 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.9 million in Q1 2026 and bottomed at $21000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $1.8 million (2023), against an average of $1.7 million.
- Peak annual rise in Interest & Investment Income reached 8000.0% in 2022, while the deepest fall reached 50.0% in 2022.
- Tracing ALT's Interest & Investment Income over 5 years: stood at $1.5 million in 2022, then surged by 33.79% to $2.0 million in 2023, then declined by 20.11% to $1.6 million in 2024, then jumped by 55.39% to $2.4 million in 2025, then advanced by 18.99% to $2.9 million in 2026.
- Per Business Quant, the three latest ALT Interest & Investment Income figures stand at $2.9 million (Q1 2026), $2.4 million (Q4 2025), and $2.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Sep 30, 2025 | 2.43 Mn |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Sep 30, 2023 | 1.88 Mn |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | 1.67 Mn |
| Dec 31, 2022 | 1.47 Mn |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | 328,000.00 |
| Mar 31, 2022 | 21,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Sep 30, 2021 | 13,000.00 |
| Jun 30, 2021 | 33,000.00 |
| Mar 31, 2021 | 42,000.00 |
| Dec 31, 2020 | 44,360.00 |
| Sep 30, 2020 | 45,127.00 |
| Jun 30, 2020 | 81,458.00 |
| Mar 31, 2020 | 151,569.00 |
| Dec 31, 2019 | 194,141.00 |
| Sep 30, 2019 | 224,058.00 |
| Jun 30, 2019 | 239,964.00 |
| Mar 31, 2019 | 185,246.00 |
| Dec 31, 2018 | 148,291.00 |
| Sep 30, 2018 | 21,100.00 |
| Jun 30, 2018 | 25,617.00 |
| Mar 31, 2018 | 31,590.00 |
| Dec 31, 2017 | 28,041.00 |
| Sep 30, 2017 | 15,372.00 |
| Jun 30, 2017 | 4,166.00 |
| Sep 30, 2016 | 202.00 |
| Jun 30, 2016 | 845.00 |
| Dec 31, 2013 | 105.00 |
| Sep 30, 2013 | 31.00 |
| Jun 30, 2013 | 1,656.00 |
| Mar 31, 2013 | 783.00 |
| Dec 31, 2012 | 4,274.00 |
| Sep 30, 2012 | 5,727.00 |
| Jun 30, 2012 | 4,819.00 |
| Mar 31, 2012 | 2,988.00 |
| Dec 31, 2011 | 6,164.00 |
| Sep 30, 2011 | 3,961.00 |
| Jun 30, 2011 | 3,381.00 |
| Mar 31, 2011 | 3,154.00 |
| Dec 31, 2010 | 706.00 |
| Sep 30, 2010 | 184.00 |
| Jun 30, 2010 | 2,582.00 |